Condition deep-dive · 6 min read

Psoriasis — supplement adjuncts to dermatological care

Updated 2026-05-12 · Reviewed by SupplementScore editors · No sponsorships

Psoriasis is a chronic immune-mediated inflammatory skin disease where the medical mainstays — topical therapies, phototherapy, methotrexate, and the IL-17 / IL-23 / TNF biologic classes — produce skin-clearance outcomes that no supplement comes close to matching. Supplements have a place as adjuncts: correcting deficiencies that may worsen disease activity, modestly reducing inflammatory load, and supporting cardiovascular risk reduction (psoriasis is a recognised cardiovascular risk modifier). The framework here is "adjunct to dermatology care," not "alternative to it."

Read this first. Moderate-to-severe psoriasis (PASI ≥10, or psoriatic arthritis) should be managed by a dermatologist. Modern biologics produce skin-clearance rates that were unthinkable a decade ago. Supplement adjuncts may help cardiovascular risk, joint symptom burden, and modest improvements in skin severity scores — but they don't replace systemic therapy in moderate-to-severe disease.

The supplements with mechanism and trial signals

Tier 1 evidence · For users with documented deficiency

Vitamin D3

Dose to a 25-OH-D target of 30–50 ng/mL; typical maintenance 1,000–2,000 IU/day

Vitamin D deficiency is common in psoriasis populations and likely contributes to disease severity. Topical vitamin D analogues (calcipotriol, calcitriol) are first-line topical therapy; oral vitamin D supplementation modestly improves PASI scores in deficient patients. Don't megadose blindly — test, target, and reassess.

Tier 2 evidence · Anti-inflammatory adjunct with cardiovascular benefit

Omega-3 (EPA/DHA)

2–4 g EPA+DHA daily; choose third-party-tested forms; take with meals

Multiple small trials and meta-analyses show modest PASI improvements with high-dose omega-3 supplementation. The cardiovascular side benefit is particularly relevant given the elevated cardiovascular risk in psoriasis. Effect sizes on skin are smaller than topical/systemic therapy but real.

Tier 2 evidence · Broad anti-inflammatory mechanism

Curcumin (bioavailable form)

1–2 g curcuminoids/day from a bioavailability-enhanced formulation (Meriva, Theracurmin, BCM-95)

Curcumin modulates NF-κB signaling, which is centrally involved in psoriatic inflammation. Small RCTs in plaque psoriasis show modest PASI score improvements when added to topical therapy. Unformulated turmeric capsules will not deliver trial-level doses; use a bioavailability-enhanced form.

Tier 2 evidence · Where folate metabolism is relevant (methotrexate users)

Folic acid (or 5-MTHF for users on methotrexate)

1–5 mg folic acid daily under dermatologist guidance during methotrexate therapy

Folate supplementation during methotrexate therapy reduces mucositis, GI side effects, and hepatotoxicity without meaningfully reducing methotrexate's efficacy. The 5-MTHF form is preferred in users with MTHFR variants. This is a prescriber-coordinated decision; folate dosing and timing matter.

Tier 3 evidence · Promising preclinical mechanism, thinner trial base

Selenium

100–200 µg/day from a yeast-based or selenomethionine form; do not exceed 400 µg/day from all sources

Some trials suggest low selenium status is associated with worse psoriasis activity; supplementation modestly improves antioxidant status. Effect on skin clearance is modest. Cap supplementation — chronic high-dose selenium is hepatotoxic and increases diabetes risk.

Tier 2 evidence · For users with significant cardiometabolic risk overlap

Berberine

500 mg 2–3× daily with meals

Psoriasis is associated with metabolic syndrome, insulin resistance, and elevated cardiovascular risk. Berberine has trial evidence for glucose, HbA1c, and lipid improvements that may be particularly relevant in this population. Don't combine without prescriber input if on metformin or rapamycin.

What to skip — common but unhelpful or risky

"Detox" / "cleanse" supplements — irrelevant to psoriasis biology; chronic herbal additive load risks GI and hepatic adverse effects.
High-dose vitamin A (retinol) — overlaps with prescription retinoids; risk of hypervitaminosis A and hepatotoxicity. Beta-carotene is acceptable in moderate doses but not therapeutic.
Echinacea — has triggered psoriasis flares in some users (case reports); avoid.
"Immune-boosting" mushroom blends in moderate-to-severe disease — particularly when on a biologic; potential immune modulation may be undesirable in either direction.
Niacin (flush form, nicotinic acid) — can trigger flares; avoid.
Topical "natural" remedies with no evidence — coal tar and salicylic acid are evidence-based topical adjuncts; coconut oil and aloe vera have limited specific evidence for psoriasis.

The dietary and lifestyle layer that often dominates supplements

Weight management — body weight is one of the strongest modifiable factors in psoriasis severity. Weight loss in overweight users reduces disease activity and improves biologic responsiveness.
Smoking cessation — smoking is a recognised psoriasis trigger and worsener.
Alcohol moderation or cessation — particularly relevant in users on methotrexate or with comorbid metabolic syndrome.
Mediterranean dietary pattern — has the best dietary-pattern evidence for reduced psoriasis activity, likely via combined inflammatory and metabolic effects.
Cardiovascular risk management — blood pressure, lipid, and glycaemic control are higher-leverage than any supplement for the long-term health agenda in psoriasis.

Practical quick-start. Coordinate the medical protocol with your dermatologist (topicals, phototherapy, systemic therapy as indicated). Test and correct 25-OH-D to 30–50 ng/mL. Add omega-3 EPA/DHA 2–3 g/day for combined skin and cardiovascular benefit. Add bioavailable curcumin if seeking additional anti-inflammatory adjunct. Address weight, smoking, alcohol, and Mediterranean dietary pattern — these have the largest absolute effect of any "non-pharmacological" intervention.

What to track

PASI score at baseline and at follow-up dermatology visits. 25-OH-D level at baseline. Cardiovascular risk markers (BP, lipid panel, HbA1c) — these matter beyond psoriasis. For users on methotrexate: liver function tests, full blood count, kidney function on the prescriber's schedule. For users on biologics: latent TB screening, vaccination status, infection screening per the biologic-specific protocol.